| Literature DB >> 16332390 |
Francis J Giles1, William T Bellamy, Zeev Estrov, Susan M O'Brien, Srdan Verstovsek, Farhad Ravandi, Miloslav Beran, Paul Bycott, Yazdi Pithavala, Heidi Steinfeldt, Steven D Reich, Alan F List, Karen W L Yee.
Abstract
AG-013736 is an oral anti-angiogenesis agent with activity against a variety of receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, c-kit, and PDGFR-beta. A phase 2 study was conducted in patients with poor prognosis AML or MDS. Twelve patients (six AML; six MDS) were treated with AG-013736 at a dose of 10mg orally daily for a median of 56 days (range, 1-248 days). Median age was 80 years (range, 58-88 years). Grade 3 or 4 drug-related toxicities included hypertension (42%), mucositis (8%) and deep venous thrombosis (8%). No objective responses occurred; two patients with MDS had stable disease for 8.3 and 6.2 months, respectively. Bone marrow expression of VEGFR-1 and VEGFR-2 was observed in 11% and 0% of patients, respectively. Sustained decreases in soluble VEGFR-2 plasma levels with concomitant elevation in plasma VEGF and placental growth factor levels were obtained during the course of therapy with AG-013736. AG-01736 had minimal biologic or clinical activity in this elderly patient population.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16332390 DOI： 10.1016/j.leukres.2005.10.024
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156